Hemispherx BioPharma, Inc (HEB) Spikes On Extension Of Rintatolimod European EAP To Pancreatic Cancer

Shares of Hemispherx BioPharma, Inc (NYSEMKT:HEB) gained more than 12.75% in the last three days of the week, after the company announced its rintatolimod European early access program (EAP) had been extended to pancreatic cancer patients. The comprehensive program will first be open in the Netherlands.

Originally, Hemispherx BioPharma, Inc (NYSEMKT:HEB)’s rintatolimod EAP was designed to provide myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) patients with access to the compound, which recently obtained approval in Argentina, becoming the first in the world approved to treat ME/CFS.

Syda Productions/Shutterstock.com

The first patient for the pancreatic cancer EAP has already been dosed. A number of additional patients are in the queue to receive the rintatolimod therapy.

“Pancreatic cancer patients generally have a poor prognosis and few therapeutic options,” Hemispherx BioPharma, Inc (NYSEMKT:HEB) CEO Thomas Equels commented. “The cancer is commonly diagnosed at an advanced stage with a five-year survival rate of roughly only seven percent for all pancreatic cancer patients. We are happy to be able to expand our EAP to a patient population for this devastating malignancy with such a clearly unmet medical need.”

Disclosures: The author holds no interest in any of the securities or entities mentioned above. He has not received compensation for this article, other than from Small Cap Nation. The statements above do not constitute recommendations. The article has been based on publicly available information, and seeks to be unbiased and non-promotional.